6月9日 - ** Summit Therapeutics 股价 SMMT.O 盘后下跌9%至13美元，该公司正在寻求股权融资
** 生物制药肿瘤学公司启动 (link) 5亿美元股票发行
** 该公司计划将募集资金净额用于其主力候选药物——肺癌药物ivonescimab的研发，以及营运资金和一般用途。
** SMMT股价周二收涨1.3%，报14.29美元，将年初至今的跌幅收窄至18%
** 这家总部位于佛罗里达州迈阿密的公司流通股约为7.762亿股，市值约110亿美元
** 据LSEG数据显示，18位分析师的平均评级为“买入”，目标价中位数为32美元
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.